Qualitest Approved for Levetiracetam Oral Solution

Qualitest announced that the FDA has approved Levetiracetam oral solution, the generic of UCB Pharma's Keppra oral solution.

Keppra oral solution is indicated for adjunct treatment in partial onset seizures in patients ≥1month old, myoclonic seizures in patients ≥12yrs old with juvenile myoclonic epilepsy, adjunct in primary generalized tonic-clonic seizures in patients ≥6yrs old with idiopathic generalized epilepsy.

Levetiracetam oral solution will be available from Qualitest in 100mg/mL dosage strength. The product is expected to be launched by mid-2012.

For more information call (800) 462-ENDO or visit www.endo.com.